Inventor
LANGEDIJK JOHANNES PETRUS MARIA
NL29 patents
⚠️ This page may combine multiple inventors who share the name “LANGEDIJK JOHANNES PETRUS MARIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN VACCINES & PREVENTION BV
27 patentsUS10729757B2Aug 4, 2020
Vaccine against RSV
JANSSEN VACCINES & PREVENTION BV15 citations91
US11229694B2Jan 25, 2022
Vaccine against RSV
JANSSEN VACCINES & PREVENTION BV9 citations84
US10953087B2Mar 23, 2021
Stabilized pre-fusion RSV F proteins
JANSSEN VACCINES & PREVENTION BV5 citations84
US10899800B2Jan 26, 2021
Stabilized soluble pre-fusion RSV F polypeptides
JANSSEN VACCINES & PREVENTION BV12 citations84
US11155583B2Oct 26, 2021
Stabilized soluble pre-fusion RSV F proteins
JANSSEN VACCINES & PREVENTION BV7 citations82
US11338031B2May 24, 2022
Vaccine against RSV
JANSSEN VACCINES & PREVENTION BV5 citations81
US10369214B2Aug 6, 2019
Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
JANSSEN VACCINES & PREVENTION BV5 citations80
US11034731B2Jun 15, 2021
Stabilized soluble pre-fusion RSV F polypeptides
JANSSEN VACCINES & PREVENTION BV5 citations79
US10968254B2Apr 6, 2021
Trimer stabilizing HIV envelope protein mutations
JANSSEN VACCINES & PREVENTION BV3 citations70
US10793607B2Oct 6, 2020
Trimer stabilizing HIV envelope protein mutations
JANSSEN VACCINES & PREVENTION BV2 citations70
US12331077B2Jun 17, 2025
Stabilized pre-fusion RSV F proteins
JANSSEN VACCINES & PREVENTION BV0 citations62
US11759514B2Sep 19, 2023
Stabilized pre-fusion RSV F proteins
JANSSEN VACCINES & PREVENTION BV0 citations62
US12234264B2Feb 25, 2025
Stabilized soluble pre-fusion RSV F proteins
JANSSEN VACCINES & PREVENTION BV0 citations61
US11998597B2Jun 4, 2024
Vaccine against RSV
JANSSEN VACCINES & PREVENTION BV0 citations61
US11896663B2Feb 13, 2024
Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
JANSSEN VACCINES & PREVENTION BV0 citations59
US11820796B2Nov 21, 2023
Trimer stabilizing HIV envelope protein mutations
JANSSEN VACCINES & PREVENTION BV0 citations59
US11801297B2Oct 31, 2023
Vaccine against RSV
JANSSEN VACCINES & PREVENTION BV0 citations59
US11732010B2Aug 22, 2023
Trimer stabilizing HIV envelope protein mutations
JANSSEN VACCINES & PREVENTION BV0 citations59
US10973907B2Apr 13, 2021
Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
JANSSEN VACCINES & PREVENTION BV0 citations59
US11723970B2Aug 15, 2023
Poxvirus vectors encoding HIV antigens, and methods of use thereof
JANSSEN VACCINES & PREVENTION BV1 citations58
US11229693B2Jan 25, 2022
Poxvirus vectors encoding HIV antigens, and methods of use thereof
JANSSEN VACCINES & PREVENTION BV1 citations58
US12577279B2Mar 17, 2026
Influenza virus vaccines and uses thereof
JANSSEN VACCINES & PREVENTION BV0 citations57
US11905314B2Feb 20, 2024
Influenza virus vaccines and uses thereof
JANSSEN VACCINES & PREVENTION BV0 citations57
US11447526B2Sep 20, 2022
Influenza virus vaccines and uses thereof
JANSSEN VACCINES & PREVENTION BV0 citations57
US12454554B2Oct 28, 2025
Influenza virus vaccines and uses thereof
JANSSEN VACCINES & PREVENTION BV0 citations55
US10711042B2Jul 14, 2020
Stabilized viral class I fusion proteins
JANSSEN VACCINES & PREVENTION BV0 citations52
US10538557B2Jan 21, 2020
Stabilized viral class I fusion proteins
JANSSEN VACCINES & PREVENTION BV0 citations52
JANSSEN PHARMACEUTICALS INC
2 patentsUS11498944B2Nov 15, 2022
Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
JANSSEN PHARMACEUTICALS INC10 citations81
US11384122B2Jul 12, 2022
Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
JANSSEN PHARMACEUTICALS INC2 citations68